- $7.94bn
- $8.06bn
- $1.16bn
- 92
- 18
- 53
- 55
Annual cashflow statement for BIO-TECHNE, fiscal year end - June 30th, USD millions except per share, conversion factor applied.
2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 229 | 140 | 263 | 285 | 168 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | -115 | 123 | 23.8 | -18.1 | 68.7 |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -5.25 | 29.3 | -69.5 | -90.6 | -10.1 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Taxes Payable | |||||
| Cash from Operating Activities | 205 | 352 | 325 | 254 | 299 |
| Capital Expenditures | -51.7 | -44.3 | -44.9 | -38.2 | -62.9 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 78.8 | -199 | -51.9 | -227 | -140 |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | 27.1 | -244 | -96.9 | -266 | -203 |
| Financing Cash Flow Items | -7.27 | -19.3 | -23.4 | -31.4 | -21.9 |
| Other Financing Cash Flow | |||||
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -184 | -62.6 | -243 | 22.6 | -122 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 45.7 | 52.5 | -26.5 | 8 | -28.8 |